Standard

Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. / Tamkovich, Svetlana N.; Yunusova, Natalia V.; Tugutova, Elena и др.

в: Asian Pacific Journal of Cancer Prevention, Том 20, № 1, 25.01.2019, стр. 255-262.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Tamkovich, SN, Yunusova, NV, Tugutova, E, Somov, AK, Proskura, KV, Kolomiets, LA, Stakheeva, MN, Grigor'eva, AE, Laktionov, PP & Kondakova, IV 2019, 'Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients', Asian Pacific Journal of Cancer Prevention, Том. 20, № 1, стр. 255-262. https://doi.org/10.31557/APJCP.2019.20.1.255

APA

Tamkovich, S. N., Yunusova, N. V., Tugutova, E., Somov, A. K., Proskura, K. V., Kolomiets, L. A., Stakheeva, M. N., Grigor'eva, A. E., Laktionov, P. P., & Kondakova, I. V. (2019). Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. Asian Pacific Journal of Cancer Prevention, 20(1), 255-262. https://doi.org/10.31557/APJCP.2019.20.1.255

Vancouver

Tamkovich SN, Yunusova NV, Tugutova E, Somov AK, Proskura KV, Kolomiets LA и др. Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. Asian Pacific Journal of Cancer Prevention. 2019 янв. 25;20(1):255-262. doi: 10.31557/APJCP.2019.20.1.255

Author

Tamkovich, Svetlana N. ; Yunusova, Natalia V. ; Tugutova, Elena и др. / Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients. в: Asian Pacific Journal of Cancer Prevention. 2019 ; Том 20, № 1. стр. 255-262.

BibTeX

@article{d06cf2d8b2184fc4a0c9520f3f5e355e,
title = "Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients",
abstract = "Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.",
keywords = "20S proteasome, ADAM-10, Ascites, Breast cancer, Exosomes, Ovarian cancer, Plasma",
author = "Tamkovich, {Svetlana N.} and Yunusova, {Natalia V.} and Elena Tugutova and Somov, {Anton K.} and Proskura, {Ksenia V.} and Kolomiets, {Larisa A.} and Stakheeva, {Marina N.} and Grigor'eva, {Alina E.} and Laktionov, {Pavel P.} and Kondakova, {Irina V.}",
note = "Creative Commons Attribution License",
year = "2019",
month = jan,
day = "25",
doi = "10.31557/APJCP.2019.20.1.255",
language = "English",
volume = "20",
pages = "255--262",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "1",

}

RIS

TY - JOUR

T1 - Protease cargo in circulating exosomes of breast cancer and ovarian cancer patients

AU - Tamkovich, Svetlana N.

AU - Yunusova, Natalia V.

AU - Tugutova, Elena

AU - Somov, Anton K.

AU - Proskura, Ksenia V.

AU - Kolomiets, Larisa A.

AU - Stakheeva, Marina N.

AU - Grigor'eva, Alina E.

AU - Laktionov, Pavel P.

AU - Kondakova, Irina V.

N1 - Creative Commons Attribution License

PY - 2019/1/25

Y1 - 2019/1/25

N2 - Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.

AB - Background: As is known, exosomes play an important role in promoting progression of cancers by increasing its invasive potential. The aim of this study was to evaluate the levels of tetraspanine-associated (ADAM-10) and tetraspanine-nonassociated proteases (20S proteasomes) in exosomes from culture medium, plasma exosomes of patients with breast tumors and plasma and ascites of ovarian tumor patients. Methods: MCF-7 and SVO-3 culture mediums and blood samples from healthy females (n = 30, HFs), patients with diffuse dyshormonal dysplasia of the breast (n=28, BBTPs), breast cancer patients (n=32, BCPs), borderline ovarian tumor patients (n=20, BOTPs) and blood and ascites samples ovarian cancer patients (n=35, OCPs) were included in the study. Exosomes from plasma, ascites and culture mediums were isolated and characterized in according to Extracellular Vesicles Society. The expression levels of 20S proteasome and ADAM-10 in exosomes were determined using flow cytometry and western blot analysis, correspondingly. Results: The subpopulation composition of the exosomes from MCF-7 culture medium and from blood plasma of HFs and breast diseases patients is similar, however CD9/CD24 subpopulation significantly increased at cell supernatant. The similar results was obtained for exosomes from SVO-3 medium and blood plasma and ascites of ovary tumor patients, but CD9/CD24 subpopulation significantly decreased at cells and illness samples, however CD63/CD24 exosomes increased significantly from cell supernatant. 20S proteasome level is significantly increased in exosomes from MCF-7 and SVO-3 culture medium, breast tumor patients and OCPs plasma in comparison to HUVEC culture medium and HFs plasma samples. At CD9-positive exosomes from BCPs plasma and MCF-7 was reveal a high expression of ADAM-10 and low expression is from BBDPs plasma and ovarian tumor patients plasma/ ascites samples. Exosomes from ascites OCP had high expression of ADAM-10 in the CD24-positive subpopulation. Conclusion: Breast and ovarian cancer development is connected with functioning of immune proteasome forms in plasma and ascites exosomes, while increased ADAM10 expression at CD9-positive exosome was associated with breast cancer and at CD24-positive subpopulation - with ovarian cancer. Obtained data confirm role of exosomal proteases in tumor progression.

KW - 20S proteasome

KW - ADAM-10

KW - Ascites

KW - Breast cancer

KW - Exosomes

KW - Ovarian cancer

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=85060542446&partnerID=8YFLogxK

U2 - 10.31557/APJCP.2019.20.1.255

DO - 10.31557/APJCP.2019.20.1.255

M3 - Article

C2 - 30678441

AN - SCOPUS:85060542446

VL - 20

SP - 255

EP - 262

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 1

ER -

ID: 18503147